Prevalence of FID and QoL in Patients with Oncological and with Haematological Malignancies

Inclusion Criteria: * Age \> 18 years * Patients with oncological (solid tumors) and with haematological malignancies (non-solid tumors, including Plasma cell myeloma, lymphoma, myeloproliferative neoplasias \[MPN\], myelodysplastic syndromes \[MDS\] and chronic leukemias) * Within four weeks prior to disease-directed systemic therapy * Participation in other trials is possible Exclusion Criteria: * Known iron deficiency with or without iron substitution p.o. or i.v. within last 8 weeks prior to inclusion into this trial * Therapy with RBC-transfusions within last 8 weeks prior to inclusion into this trial * Therapy with ESA within last 8 weeks prior to inclusion into this trial * Malignancies with acute need for therapeutic intervention (e.g. acute leukemias, superior vena cava obstruction, etc.) * Pregnancy * Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the trial * Inability to give consent